全文获取类型
收费全文 | 180篇 |
免费 | 20篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 29篇 |
妇产科学 | 2篇 |
基础医学 | 22篇 |
口腔科学 | 4篇 |
临床医学 | 15篇 |
内科学 | 49篇 |
皮肤病学 | 2篇 |
神经病学 | 4篇 |
特种医学 | 4篇 |
外科学 | 39篇 |
综合类 | 1篇 |
预防医学 | 2篇 |
药学 | 4篇 |
肿瘤学 | 24篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 6篇 |
2020年 | 6篇 |
2019年 | 9篇 |
2018年 | 6篇 |
2017年 | 8篇 |
2016年 | 7篇 |
2015年 | 17篇 |
2014年 | 9篇 |
2013年 | 10篇 |
2012年 | 10篇 |
2011年 | 10篇 |
2010年 | 11篇 |
2009年 | 8篇 |
2008年 | 9篇 |
2007年 | 9篇 |
2006年 | 12篇 |
2005年 | 12篇 |
2004年 | 4篇 |
2003年 | 4篇 |
2002年 | 2篇 |
2001年 | 6篇 |
2000年 | 12篇 |
1999年 | 4篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1996年 | 3篇 |
排序方式: 共有202条查询结果,搜索用时 0 毫秒
91.
Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma 总被引:1,自引:0,他引:1
Karagol H Saip P Uygun K Kucucuk S Aydiner A Topuz E 《Medical oncology (Northwood, London, England)》2006,23(4):543-548
Background Prognostic factors related to survival in patients with inoperable metastatic or recurrent endometrial carcinoma (MREC) have
remained unclear due to lack of clinical trials. The management of these patients is also controversial. This study was performed
to compare the efficacy and toxicity profiles of two different systemic therapies (chemotherapy vs hormonal therapy) given
for the treatment of patients with MREC and to identify the impact of various prognostic factors on the survival.
Methods Between 1992 and 2004, 44 patients with MREC were admitted to our oncology department. Four cases were excluded from this
retrospective study because of lack of data in their charts. Age, presence of other systemic diseases (such as diabetes mellitus,
hypertension), histological type, tumor grade, stage, disease-free interval, site of recurrence or metastasis, systemic treatment
modality, overall response to treatment, and duration of time to progression were evaluated as prognostic factors. Cox regression
analysis was performed for identification of independent prognostic factors and differences between patients characteristics
of two treatment groups were calculated by the chi-square or t test.
Results The median follow-up was 18 mo (range 3–113). The overall response rates for chemotherapy and hormonal therapy group were
42% and 41%, respectively (p>0.05). The median time to progression was 4 mo for the chemotherapy group and 5 mo for the hormonal therapy group (P>0.05). The median survival after metastasis or recurrence was 11 mo for the chemotherapy group and 16 mo for the hormonal
therapy group (p>0.05). In the group of chemotherapy, grade 3–4 hematologic and nonhematologic toxicities were seen in eight and two, patients,
respectively. No grade 3–4 toxicities were noted in patients treated with hormonal therapy. In multivariate analysis, only
time to progression (p=0.001) and grade (p=0.04) were the independent prognostic factors on survival after metastasis or recurrence.
Conclusion Histological differentiation and duration of time to progression are predictive factors for survival after metastasis or recurrence
in the whole group. The efficacy of two different groups of treatment in these patients appears to be similar. But the chemotherapy
may have some disadvantageous in terms of toxicity. This study supports a future randomized prospective trial of hormonal
therapy vs chemotherapy in patients with MREC. 相似文献
92.
Irfan Cicin Hakan Karagol Ufuk Usta Atakan Sezer Sernaz Uzunoglu Rusen Alas-Cosar Tarkan Yetisyigit Kazim Uygun 《Medical oncology (Northwood, London, England)》2009,26(3):335-343
The aim of this study is to reveal likely demographic, clinical, and pathological differences among hormone receptor negative
breast cancer patients according to their HER-2 status. The medical records of hormone receptor negative breast cancer patients
with known HER-2 status between January 1999 and December 2006 were reviewed, retrospectively. A total of 91 cases were included
in the study (68 HER-2 negative cases and 23 HER-2 positive cases). The results obtained showed that median age, menarche
age, childbearing age, number of children, menopause age, and body-mass indexes were similar in both groups. The HER-2 negative
patients had more family history of breast cancer than HER-2 positive patients (13.2% and 0%, respectively, P = 0.091). Eighty-three patients received neoadjuvant/adjuvant chemotherapy. Recurrence occurred in 41 (46.6%) patients. Neither
recurrence nor disease-free survival of those patients was associated with HER-2 status. Tumor size (P = 0.042) and number of involved lymph nodes (P = 0.001) were found to be independent prognostic factors for disease-free survival. A tendency for more frequent cerebral
metastasis was found in HER-2 positive advanced stage patients (P = 0.052). HER-2 positive patients were less responsive to taxanes (P = 0.071). The number of involved lymph nodes (P = 0.004) and HER-2 status (P = 0.043) were found to be prognostic factors for overall survival. HER-2 positive and negative patients should be followed
and treated with different strategies. HER-2 positive patients are at least as resistant to systemic therapies as the HER-2
negative patients. Genetic counseling should be routinely provided to triple negative patients and their families. HER-2 positive
patients may be candidates for prophylactic treatment strategies concerning cerebral metastasis. 相似文献
93.
94.
Berendsen TA Izamis ML Xu H Liu Q Hertl M Berthiaume F Yarmush ML Uygun K 《Transplantation proceedings》2011,43(5):1484-1488
Introduction
The gold standard in organ preservation is static cold storage (SCS) using University of Wisconsin solution (UW). Although it is well-known that there is a finite limit to SCS preservation, and that there is a correlation between the adenosine triphosphate (ATP) levels and organ function post-preservation, a quantitative relationship has not been established, which is important in understanding the fundamental limitations to preservation, minimizing cold ischemic injury, and hence maximizing use of the donor organ pool.Aim
This study determines the time limits of cellular viability and metabolic function during SCS, and characterizes the relationship between cellular viability and energetic state using clinically relevant techniques in organ preservation.Methods
Rat livers were procured and stored using conventional storage in UW solution at 4°C. Viability was assessed by determining the amount of viable hepatocytes and intracellular ATP content after 0, 24, 48, 72, and 120 hours of storage.Results
Numbers of viable hepatocytes that were isolated from these livers decreased steadily during SCS. After 5 days, viable hepatocytes decreased from 25.95 × 106 to 0.87 × 106 cells/gram tissue. Intracellular ATP content decreased from 9.63 to 0.93 moles/g tissue. Statistical analysis of variance established a linear relation for both parameters as a function of time (P < .05).Conclusion
The linear correlation between hepatocyte viability, ATP content, and storage time suggests a shared physiological foundation. These findings confirm ATP as direct predictor for organ quality in the context of liver preservation, which will aid quantitative assessment of donor organs for various applications. 相似文献95.
96.
97.
BACKGROUND: Helicobacter pylori eradication rates have tended to decrease recently, mostly due to increasing antibiotic-resistance. The present study aimed to compare the efficacy of bismuth-based quadruple regimen with proton pump inhibitor-based triple regimen for eradication of H. pylori. METHODS: Consecutive H. pylori-positive patients with non-ulcer dyspepsia were randomized into one of two regimens: (i) bismuth subsalicylate 300 mg q.i.d., lansoprazole 30 mg b.i.d., tetracycline 500 mg q.i.d. and metronidazole 500 mg t.i.d. (BLTM group) for 14 days; (ii) lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d. (LAC) for 14 days. Gastroscopy and (14)C-Urea breath test (UBT) were performed before enrollment, and UBT only was repeated for 6 weeks after treatment. RESULTS: A total of 240 patients were randomized into groups and 212 of them completed the protocols. The 'intention-to-treat' (ITT) and 'per protocol' (PP) H. pylori eradication rates were 70% (95%CI 61-78) and 82.3% (95%CI 74-89) in the BLTM group, and 57.5% (95%CI 48-66) and 62.7% (95%CI 53-71) in the LAC group. The BLTM treatment achieved a significantly better eradication rate compared with LAC treatment in PP analysis (82.3% vs. 62.7%, P = 0.002). Mild to severe side-effects, which were more frequent in the BLTM group, were reported in 18.2% of the patients. CONCLUSION: The bismuth-based quadruple regimen achieved a better eradication rate compared with proton pump inhibitor-based triple regimens as a first-line eradication option for H. pylori in our population. 相似文献
98.
Splenic hemangiopericytoma is a very rare tumor. So far only 10 patients (9 adults, 1 child) have been reported in the literature and all of them were treated with total splenectomy. Herein, we report the first infant case of the splenic hemangiopericytoma in a 10-month-old girl and the first case that was treated with partial splenectomy for splenic hemangiopericytoma. 相似文献
99.
Hazar V Karasu GT Uygun V Akcan M Küpesiz A Yesilipek A 《Journal of pediatric hematology/oncology》2010,32(8):e317-e322
There is limited data about the long-term treatment outcome and prognosis of childhood acute lymphoblastic leukemia (ALL) in developing countries. Our study was designed to assess survival data and identify risk factors. Data of 142 children with ALL who were treated with a modified BFM 95 protocol between 1997 and 2007 were evaluated. The median age was 4.3 years. Complete remission (CR) rate after induction phase was 93.5%; with 2.1% induction-related mortality and 0.7% having resistance disease. Of complete responders, 67.1% are in continuous CR with a median follow-up of 63 months (range: 24 to 153 mo). Treatment-related mortality was 17.7% and the total rate of treatment abandonment was 3.5%. The probability of event-free survival was 67.3% (95% confidence interval 59.3-75.3) at 4 years and 63.2% (95% confidence interval 54.4-72.0) at 8 years. This report examines children with ALL treated with a modified ALL-BFM 95 protocol in a tertiary care center in Turkey with adequate follow up and demonstrates the need for improvements especially for patients with unfavorable risk group and strategies to reduce deaths from infection in CR to keep pace with cure rates in developed countries. 相似文献
100.
Bulent Antmen Zeynep Karaka Mehmet Akif Yeilipek Osman Alphan Küpesiz lgen amaz Vedat Uygun Erdal Kurtolu Gonul Oktay Gonul Aydogan Mehmet Akn Zafer Salcioglu Canan Vergin Elif Güler Kazanc Selma Ünal Ümran alkan Yusuf Ziya Aral Emine Türkkan Adalet Meral Güne Bahattin Tun Fatma Gümrük Aylin Canbolat Ayhan Murat Sker Ahmet Ko Yeim Oymak Mehmet Ertem etin Timur Yldz Yldrmak Gülersu rken Hilmi Apak Betül Biner Tuba Gürleyen Eren Yasemin Ik Balc Ülker Koak Gülsün Karasu Diyar Akkaynak Türkan Patrolu 《European journal of haematology》2019,102(2):123-130